Medicines Co preps for FDA, EMA submissions with positive top-line pivotal data for carbavance - FierceBiotech

FierceBiotech

Medicines Co preps for FDA, EMA submissions with positive top-line pivotal data for carbavance FierceBiotech The Medicines Company expects to submit an NDA early next year to the FDA for its Carbavance (meropenem-vaborbactam). That's on the heels of top-line pivotal data to treat patients with complicated urinary tract infections (cUTI) that demonstrated ... The Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE®Business Wire (press release) The Medicines Company's Carbavance successful in late-stage study in cUTISeeking Alpha all 4 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFx7OPOl_g1ZFR76UsXRDvvKdwTnw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779141870043&ei=dllxV_DIIZfH3QGzg5fgBg&url=http://www.fiercebiotech.com/biotech/medicines-co-preps-for-fda-ema-submission-positive-top-line-pivotal-data-for-carbavance
via IFTTT